What is HC Wainwright’s Forecast for BioNTech Q1 Earnings?

BioNTech SE (NASDAQ:BNTX) – Equities research analysts at HC Wainwright raised their Q1 2025 earnings estimates for shares of BioNTech in a note issued to investors on Tuesday, April 1st. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($2.34) per share for the quarter, up from their previous forecast of ($3.42). HC Wainwright currently has a “Buy” rating and a $145.00 target price on the stock. The consensus estimate for BioNTech’s current full-year earnings is ($3.88) per share. HC Wainwright also issued estimates for BioNTech’s Q2 2025 earnings at ($2.52) EPS, Q3 2025 earnings at ($1.23) EPS, Q4 2025 earnings at $0.58 EPS and FY2025 earnings at ($5.51) EPS.

BioNTech (NASDAQ:BNTX) last released its earnings results on Monday, March 10th. The company reported $1.08 EPS for the quarter, topping analysts’ consensus estimates of $0.38 by $0.70. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The firm had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.24 billion. During the same quarter in the previous year, the business earned $1.90 EPS. The business’s quarterly revenue was down 19.5% compared to the same quarter last year.

Several other equities analysts have also issued reports on the company. Truist Financial assumed coverage on BioNTech in a research report on Friday, January 10th. They set a “buy” rating and a $172.00 target price for the company. Citigroup began coverage on shares of BioNTech in a report on Thursday, March 13th. They set a “buy” rating and a $145.00 price objective for the company. Wells Fargo & Company initiated coverage on shares of BioNTech in a report on Wednesday, December 11th. They issued an “overweight” rating and a $170.00 target price on the stock. Morgan Stanley decreased their price target on shares of BioNTech from $145.00 to $139.00 and set an “overweight” rating for the company in a report on Tuesday, March 11th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $171.44 price objective on shares of BioNTech in a research note on Tuesday, March 11th. Three equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, BioNTech currently has an average rating of “Moderate Buy” and an average price target of $143.44.

BioNTech Trading Down 4.3 %

NASDAQ BNTX opened at $88.05 on Friday. BioNTech has a 12 month low of $76.53 and a 12 month high of $131.49. The stock has a 50-day simple moving average of $108.81 and a 200 day simple moving average of $112.88. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $21.13 billion, a PE ratio of -41.93 and a beta of 1.07.

Institutional Investors Weigh In On BioNTech

Institutional investors have recently bought and sold shares of the company. Jones Financial Companies Lllp grew its stake in shares of BioNTech by 110.3% during the 4th quarter. Jones Financial Companies Lllp now owns 469 shares of the company’s stock worth $53,000 after acquiring an additional 246 shares in the last quarter. Quintet Private Bank Europe S.A. grew its position in BioNTech by 823.5% in the fourth quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company’s stock valued at $88,000 after purchasing an additional 700 shares in the last quarter. Allianz SE acquired a new stake in BioNTech in the 4th quarter valued at $90,000. GAMMA Investing LLC increased its stake in BioNTech by 48.2% in the 4th quarter. GAMMA Investing LLC now owns 923 shares of the company’s stock valued at $105,000 after buying an additional 300 shares during the last quarter. Finally, Generali Investments CEE investicni spolecnost a.s. acquired a new position in shares of BioNTech during the 4th quarter worth about $137,000. Institutional investors own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.